Drug companies heavy advertising, light research and development media: not all enterprises.

category:Global
 Drug companies heavy advertising, light research and development media: not all enterprises.


According to Xinhua news agency, more than 40 of the more than 140 pharmaceutical listed companies in China accounted for 30% of the total sales revenue, and the highest reached 66%. This means that some manufacturers earn more than 6 cents per 1 yuan in advertising. Such behavior only in the downstream is obviously very harmful to the healthy development of pharmaceutical enterprises in China. China is a big country with a large population. Under the background of male crown global of the per capita infusion of antibiotics and the use of antibiotics, our country is an unfolding superpower of drug use, and the market demand is great. So as long as manufacturers can effectively promote, it is easy to get a huge market return. At the same time, China has not established a perfect medicine system, people lack of pharmaceutical guidance in the selection of medicine, community medical treatment is not in place, peoples medical knowledge is relatively weak, advertising is more inducible to people, and more easily lead to the phenomenon of choosing drugs to follow the advertisement. The problem is more than that. There are relatively weak problems in the supervision of medical advertisements in China. Many God medicine advertisements have occupied the prominent position of publicity media for many years, either exaggerating the efficacy or covering up the danger, but not seeing the next shelf. Coupled with the implementation of the policy of taking drugs to support doctors, medication is an important source of interest for hospitals, which naturally will greatly increase the dosage of drugs. To a certain extent, it also allows pharmaceutical companies to focus on drug sales, without intention to research and develop. One reason is that the evaluation system of drug effect is not perfect, and there is no mechanism to improve the product. Whether a drug is used in patients is really effective and lacks detailed assessment. If the specification says that the efficiency is 95%, then it can stand at the end of sales for 95% years in a few decades. As long as there is no large area of adverse reactions, there will be little doubt. One of the most typical examples is that a product, known to be able to dissolve oxygen in liquid, can also rely on propaganda for a period of time in the pharmaceutical market, until some people question how oxygen can dissolve in water, so that the drug that goes against the basic principles of science is kicked out of the market. Since the sales environment is so comfortable, efforts to improve or develop innovation will really lose momentum. It is entirely different from the sales sector to create a stable environment and a comfortable environment. Because of the introduction of a new variety, it may be behind hundreds of varieties of failure, which is a huge initial investment. When advertising is launched today, the benefits may be seen tomorrow, tens of millions or billions of research and development inputs may not be effective after many years. And even if we are lucky enough to get a new product, whether it can be recognized by the industry, there is still a lot of uncertainty. Due to the lack of enough strength in the medical field in China, our products want to be recognized by the authority of the industry, and there is a great gap between them. This decides, in the medical field, if not enough money to the adequate volume, to make innovation, as a huge gamble, the cost of failure is extremely high. Of course, another problem is that our patent awareness of drugs is rather weak. Think about the intellectual property of the patent law that has not been put forward in the patent law of 1985~1993 years. How could it be possible to cultivate a high sense of innovation in a short period of time? It should be said that the research and development of pharmaceutical enterprises is not a strong sense of innovation, not all is the cause of the enterprise, to reverse the profit model of the pharmaceutical enterprises that can make money only by propaganda, and need all efforts and even the change of the whole environment. Ultimately, we must rely on the market mechanism, so that R & D innovative pharmaceutical companies to get a substantial return. Source: Zheng Shanhai, editor in chief of Beijing News: Ji Ke _b6492 And even if we are lucky enough to get a new product, whether it can be recognized by the industry, there is still a lot of uncertainty. Due to the lack of enough strength in the medical field in China, our products want to be recognized by the authority of the industry, and there is a great gap between them. This decides, in the medical field, if not enough money to the adequate volume, to make innovation, as a huge gamble, the cost of failure is extremely high. Of course, another problem is that our patent awareness of drugs is rather weak. Think about the intellectual property of the patent law that has not been put forward in the patent law of 1985~1993 years. How could it be possible to cultivate a high sense of innovation in a short period of time? It should be said that the research and development of pharmaceutical enterprises is not a strong sense of innovation, not all is the cause of the enterprise, to reverse the profit model of the pharmaceutical enterprises that can make money only by propaganda, and need all efforts and even the change of the whole environment. Ultimately, we must rely on the market mechanism, so that R & D innovative pharmaceutical companies to get a substantial return.